Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party

Blood (2016) 128 (22): 2266.

https://doi.org/10.1182/blood.V128.22.2266.2266

Published: 2016

Journal Articles

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

Blood (2008) 112 (11): 1070.

https://doi.org/10.1182/blood.V112.11.1070.1070

Published: 2008

Journal Articles

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Donald Milligan, MD, Ann Hunter, MD, Gordon Cook, MD, Adrian Bloor, MD, Charles Craddock, MD, Lynny Yung, MD, Anne Parker, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1666.

https://doi.org/10.1182/blood.V110.11.1666.1666

Published: 2007

Journal Articles

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

Alan K. Burnett, MD, Robert K. Hills, DPhil, David Grimwade, MD, Anthony H. Goldstone, MD, Ann Hunter, MD, Don Milligan, MD, Archie G. Prentice, MD, Nigel H. Russell, MD, Keith Wheatley, DPhil

Blood (2007) 110 (11): 589.

https://doi.org/10.1182/blood.V110.11.589.589

Published: 2007

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, MD, Anthony H. Goldstone, DM, Donald Milligan, FRCP, Ann Hunter, FRCP, Archie G. Prentice, FRCP, Nigel H. Russell, MD, Brenda Gibson, FRCP, Keith Wheatley, DPhil, Robert K. Hills, MA, MSc, DPhil

Blood (2006) 108 (11): 13.

https://doi.org/10.1182/blood.V108.11.13.13

Published: 2006

Journal Articles

The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, RCPath,MRCPI, MA, MB, Robert K. Hills, MA,MSc, DPhil, Nigel H. Russell, MD,FRCP,FRCPath, John Yin, MRCP, MRCPath, Ann Hunter, Dominic Culligan

Blood (2006) 108 (11): 1950.

https://doi.org/10.1182/blood.V108.11.1950.1950

Published: 2006

Journal Articles

A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantion (PBSCT).

Ann Hunter, FRCP, FRCPath, Prem Mahendra, FRCP FRCPath, Keith Wilson, FRCP FRCPath, Paul Fields, PhD FRCP FRCPath, Gordon Cook, PhD FRCP FRCPath, Andrew Peniket, FRCP FRCPath, Charles Crawley, FRCP FRCPath, Rob Hallam, PhD FICR, Roger Hickling, BSc, Richard Palmer, PhD, Robert Marcus, FRCP, FRCPath

Blood (2006) 108 (11): 45.

https://doi.org/10.1182/blood.V108.11.45.45

Published: 2006

Journal Articles

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Ronjon Chakraverty, MD, Maria Dimopoulou, MD, Julie Glanville, MD, Kirsty Thomson, MD, Karl Peggs, MD, Donald Milligan, MD, Gordon Cook, MD, Graham Jackson, MD, Anne Parker, MD, Ann Hunter, MD, Nigel Russell, MD, Rachel Pearce, Stephen Mackinnon, MD

Blood (2006) 108 (11): 2901.

https://doi.org/10.1182/blood.V108.11.2901.2901

Published: 2006

Journal Articles

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Kirsty J. Thomson, MD, Emma C. Morris, MD, Don Milligan, MD, Gordon Cook, MD, Jim Cavet, MD, Charles Craddock, MD, Ann Hunter, MD, Steve Schey, MD, Anne Parker, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Karl S. Peggs, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 401.

https://doi.org/10.1182/blood.V106.11.401.401

Published: 2005

Journal Articles

Harvesting for “A Rainy Day”: A Retrospective Analysis of Its Cost-Effectivenes and Ethical Implications.

Miguel Ortin, MD, Sue Bricknell, Jane Kimber, Lynn Stirrup, Dietmar Hofer, MD, Martin J. Dyer, Ann Hunter, MD

Blood (2005) 106 (11): 2924.

https://doi.org/10.1182/blood.V106.11.2924.2924

Published: 2005

Journal Articles

A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies.

Miguel Ortin, MD, Sue Bricknell, Sheila Gribben, Lynn Stirrup, Martin Dyer, Ann Hunter, MD

Blood (2005) 106 (11): 5484.

https://doi.org/10.1182/blood.V106.11.5484.5484

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

Journal Articles

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

William J. Kell, Alan K. Burnett, Raj Chopra, John A. L. Yin, Richard E. Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G. Prentice, Donald W. Milligan

Blood (2003) 102 (13): 4277–4283.

https://doi.org/10.1182/blood-2003-05-1620

Published: 2003

Journal Articles

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

Blood (2002) 100 (9): 3121–3127.

https://doi.org/10.1182/blood-2002-03-0701

Published: 2002

Journal Articles

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Blood (2002) 100 (9): 3108–3114.

https://doi.org/10.1182/blood-2002-02-0506

Published: 2002

Journal Articles

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Blood (2002) 99 (3): 1071–1078.

https://doi.org/10.1182/blood.V99.3.1071

Published: 2002

NARROW

Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.

A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantion (PBSCT).

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Harvesting for “A Rainy Day”: A Retrospective Analysis of Its Cost-Effectivenes and Ethical Implications.

A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only